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Objective: Limited data exist on the optimum level of systolic blood pressure (BP) in thrombolyzed 
patients with acute ischemic stroke (AIS). We aimed to determine the effects of intensive BP 
lowering, specifically in patients with severe AIS who participated in the international, Enhanced 
Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED). 
Methods: Pre-specificed subgroup analyzes of the BP arm of ENCHANTED, a multicenter, partial-
factorial, open, blinded outcome assessed trial, in which 2227 thrombolysis-eligible and treated AIS 
patients with elevated systolic BP (>150 mmHg) were randomized to intensive (target 130-140 
mmHg) or guideline-recommended (<180 mmHg) BP management.  Severe stroke was defined by 
computed tomography or magnetic resonance angiogram confirmation of large-vessel occlusion, 
receipt of endovascular therapy, final diagnosis of large artery atheromatous disease, or high (>10) 
baseline neurological scores on the National Institutes of Health Stroke Scale (NIHSS).  The 
primary efficacy outcome was death or any disability (modified Rankin scale [mRS] scores 2-6). 
The key safety outcome was intracranial hemorrhage (ICH).  Treatment effects estimated in logistic 
regression models are reported as odds ratios with 95% confidence intervals (CIs). 
Results:  There were 1,311 patients (mean age 67 years; 37% female; median baseline NIHSS of 
11 [range 6.0-15.0]) with severe AIS.  Overall, there was no significant difference in the primary 
outcome of death or disability.  However, intensive BP lowering significantly increased mortality 
(odds ratio 1.52, 95% CI 1.09-2.13; P=0.014) compared to guideline BP lowering, despite 
significantly lowering clinician-reported ICH (odds ratio 0.63, 95% CI 0.43-0.92; P=0.016). 
Conclusion: Intensive BP lowering is associated with increased mortality in patients with severe 
AIS despite lowering the risk of ICH.  Further randomized trials are required to provide reliable 
evidence over the optimum systolic BP target in the most serious type of AIS. 





Guidelines have understandably extrapolated the conventionally-recommended conservative 
level of blood pressure (BP) control (<180 AND <105 mmHg) in patients with acute ischemic 
stroke (AIS) eligible for reperfusion therapy with intravenous thrombolysis to those patients 
with large vessel occlusion, the most serious type of AIS [1].  However, as there is limited direct 
randomized evidence, wide ranging opinions exist as to the most appropriate level of systolic 
BP control before, during and after, endovascular thrombectomy for large vessel occlusion AIS 
[2].  The situation appears complex, with poor functional outcome associated with high pre-
endovascular thrombectomy systolic BP (>140mmHg) [3], low intra-procedural systolic BP 
(<140 mmHg) with general anaesthesia [4], and high systolic BP immediately post 
endovascular thrombectomy (>160mmHg) [5]. Moreover, post-hoc analyses of the Multicenter 
Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the 
Netherlands (MR CLEAN) trial suggest J- or U-shaped correlations of baseline systolic BP and 
adverse outcome [3].  All these data suggest that ‘moderate’ levels of systolic BP control could 
provide the optimal outcome from endovascular thrombectomy, but there are ongoing concerns 
that BP lowering treatment may increase the risk of harms in large vessel occlusion AIS [6], 
particularly where the AIS lesion is large [7]. 
Recently, the BP arm of the Enhanced Control of Hypertension and Thrombolysis Stroke Study 
(ENCHANTED) showed no overall benefit of intensive BP reduction (systolic BP target 130-
140 mmHg) compared with guideline BP control (<180 mmHg) in thrombolysis-eligible AIS 
patients [8, 9], despite a significant reduction in intracranial hemorrhage (ICH).  However, only 
a modest 5 mmHg systolic BP separation was achieved between the randomized groups, most 
AIS patients had mild-moderate neurological severity (median NIHSS score 7), and few had 
endovascular thrombectomy which was being introduced into routine clinical practice during 




by neurological severity and across other pre-specified subgroups, we wished to undertake more 
detailed investigation of the effects of intensive versus guideline systolic BP lowering in 
patients with severe AIS. 
MATERIALS AND METHODS 
Study design 
These are post-hoc analyzes of ENCHANTED, an international, 2x2 partial-factorial, 
multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial, as outlined 
elsewhere [8, 9].  In brief, the study included adult patients (age ≥18 years) with a clinical 
diagnosis of AIS confirmed by brain imaging who fulfilled standard criteria for thrombolysis 
treatment, including having a systolic BP ≤185 mmHg.  The BP arm recruited 2227 participants 
with elevated systolic BP (≥150 mmHg), where the treating clinician was uncertain of the 
balance of benefits and risks of different intensities of BP control over 72 hours (or hospital 
discharge [or death], if earlier) post-thrombolysis, between March 3, 2012 and April 30, 2018.  
Participants were randomly assigned to a strategy of intensive BP lowering (target systolic BP 
130–140 mmHg <60 mins) or guideline-recommended BP lowering (target systolic BP <180 
mmHg) within 6 hours of intravenous alteplase. 
Definition of Severe Stroke 
For these analyzes, we pragmatically defined severe stroke as having at least one of the 
following characteristics: large vessel occlusion confirmed either on computed tomography or 
magnetic resonance angiogram (n=84) or use of endovascular thrombectomy (n=42), or 
clinician-reported final diagnosis of large artery atheromatous disease (due to significant intra- 
or extracranial atheroma) (n=952); and all patients with a high baseline score (>10) on the 





Socio-demographic and clinical details were obtained at the time of randomization.  BP 
lowering treatment was undertaken according to standardized protocols based upon the use of 
locally available intravenous (bolus and infusion), oral and/or topical antihypertensives.  All 
patients were managed in an acute stroke unit, or alternative environment with appropriate 
staffing and monitoring, and received active care with best practice management according to 
guidelines.  Non-invasive BP monitoring was undertaken using an automated device applied to 
the non-hemiparetic arm (or right arm in situations of coma or tetraparesis) with the patient 
resting supine for >3 minutes according to a standard protocol.  BP measurements were 
recorded every 15 minutes for 1 hour, and 6-hourly from 1 to 24 hours, post-thrombolysis, and 
then twice daily for 7 days (or hospital discharge or death, if earlier).  Neurological status, 
according to the NIHSS and Glasgow Coma Scale (GCS) scores, was assessed at baseline, and 
at 24 and 72 hours, and 7 days.  Brain imaging (computed and/or magnetic resonance imaging) 
was conducted at baseline, and at 24 hours, and additionally if clinically indicated; analyzes 
were undertaken centrally for diagnoses of categories of ICH by trained readers blind to clinical 
details and treatment allocation.  Clinical outcome data were collected at 24 and 72 hours, 7 
days (or at hospital discharge if earlier), and 28 and 90 days. 
Outcomes 
The primary efficacy outcome was death or any disability, defined as scores 2-6 on the modified 
Rankin scale (mRS).  Secondary outcomes included death or major disability (mRS scores 3-
6), all-cause specific mortality, and death or neurological deterioration (≥4 points decline in 
NIHSS) within 24 and 72 hours.  The key secondary safety outcome was any ICH reported by 
investigators with or without central adjudication of relevant brain imaging within 7 days post-
randomization.  Other safety outcomes included the topography of ICH identified on centrally 




whereby an ICH leads to significant neurological deterioration and/or death, as defined by 
several criteria used in other studies [8].  
Statistical analysis 
Dichotomous logistic regression analyses were used to assess the treatment effect. Data were 
presented as odds ratios and 95% confidence intervals (CI).  A priori [9], the primary analysis 
for the effect of intensive versus guideline-recommended BP lowering was unadjusted. 
Sensitivity analyses were performed on the subgroup of high baseline NIHSS (>10) and final 
diagnosis of large artery atheromatous disease to confirm the consistency of any association.  
All tests were two-sided and the significance level was set at 5%. SAS software version 9.3 was 
used for analyses. 
RESULTS 
There were 1,311 patients (mean age 67±12 years; 37% female; median baseline NIHSS of 11 
[range 6.0-15.0]) with severe AIS included in these analyzes (Figure I in the Supplementary 
Files).  Computed tomography or magnetic resonance angiographic imaging was performed in 
84 patients (6.4%), with large vessel occlusion identified in 56 (4.3%) and endovascular 
thrombectomy performed in 42 (3.2%) patients.  In our severe stroke group there were no 
significant differences in the baseline characteristics or management over 7 days between the 
guideline and intensive BP lowering groups (Table 1 and Table I in Supplementary Files).  
There were 938 (72%) patients with a history of hypertension, and 576 (44%) were on prior 
antihypertensive therapy.  In keeping with the randomized allocation, patients in the intensive 
BP lowering group were more likely to have received BP lowering therapy, in particular 
intravenous agents within 24 hours and all types of therapy from 24 hours to Day 7 (Table I in 
Supplementary Files); with significant between-group systolic BP differences post-




Overall, there was no significant difference in the primary outcome of death or disability (mRS 
scores 2-6), between the guideline and intensive BP lowering in patients with severe AIS (Table 
2 and Figure 2).  However, there was a significant reduction in clinician-reported ICH with 
intensive BP lowering (odds ratio 0.63, 95% CI 0.43-0.92; P=0.016), but this was not significant 
for the key safety outcome of any ICH (P=0.065).  There were no significant treatment 
differences in symptomatic ICH across a range of definitions but there was a significant increase 
in deaths (odds ratio 1.52, 95% CI 1.09-2.13; P=0.014) in the intensive BP lowering group, 
compared to guideline BP lowering (Table 2). 
Sensitivity analyses demonstrated a significant association between high baseline NIHSS (>10) 
and death within 90 days (odds ratio 1.57, 95% CI 1.08-2.28; P=0.018) and death or 
neurological deterioration in 7 days (odds ratio 1.57, 95% CI 1.07-2.31; P=0.021) (Table I in 
Supplementary Files). 
DISCUSSION 
In these post-hoc secondary analyzes of the ENCHANTED study, we have shown that in the 
subgroup of severe AIS patients, there were diverging effects of increased death and reduced 
ICH from intensive BP lowering, but without any influence on the overall odds of good 
functional outcome.  
A widely accepted hypothesis is that any potential benefits of intensive BP lowering in reducing 
the risk of re-perfusion ICH are offset by worsening functional outcome from exacerbating the 
ischemic penumbra [10, 11].  However, previous meta-analyses have not clearly shown that 
early BP lowering treatment adversely affects the likelihood of death, dependency, stroke 
recurrence, and other vascular outcomes [7].  Overall, the BP arm of ENCHANTED showed 
that BP lowering treatment is safe, and appears to reduce the likelihood of ICH.  However, as 




independent of the ischemic lesion, although the systolic BP differences over time between 
randomized groups were small.   
Our finding of increased mortality from intensive BP lowering has physiological rationale from 
a cerebral hemodynamic perspective: moderate-severe AIS is associated with greater cerebral 
blood flow velocity asymmetries between unaffected and affected hemispheres, worsened 
cerebral autoregulation ipsilateral to the infarct, and bilateral neurovascular coupling 
impairment [12].  It is accepted that in ambulatory subjects with mild and moderate 
hypertension, the brain is able to quickly adapt the cerebral vasculature to protect against 
hypoperfusion when antihypertensive therapy is commenced [13].  However, in those with 
chronic hypertension, akin to over 70% of patients within this study, the autoregulatory curve 
is presumed to have shifted to right, although individual variability exists as to the magnitude 
of such a shift, or indeed its timing [14].  Unfortunately, this shift may potentiate an increased 
likelihood of harm as the lower limit of autoregulation and acute hypoperfusion in the presence 
of large vessel occlusion may explain why intensive BP lowering has adverse outcome. 
However, in hypertensives without acute cerebrovascular disease, as included in the 
randomized trial of intensive versus standard BP control (SPRINT) trial, the intensive 
(<120mmHg) BP target was associated with lower incidence of stroke and overall lower all-
cause mortality. Our study does not support patients with acute (or acute on chronic) 
hypertension and AIS being treated with a similar intensive strategy [15].  
Nonetheless, intensively lowering BP was associated with less ICH.  Previously, very limited 
small retrospective analyses have examined clinical outcome in those receiving BP lowering 
pre-thrombolysis.  This showed no relationship to higher rates of ICH or poor outcome [10].  
Our results suggest that as ICH occurrence was lower in the intensively managed group; ICH 
occurrence alone does not explain the increased risk of death in the intensively lowered group 




ENCHANTED was first randomized clinical trial to examine the effects of intensive BP 
lowering in thrombolyzed patients, and herein we have attempted to explore the effects of such 
treatment in those with severe AIS. Prior data from subgroup analyzes of the angiotensin-
receptor blocker candesartan for treatment of acute stroke (SCAST) trial demonstrated no 
association with composite vascular endpoint or functional outcome in those receiving blood 
pressuring lowering and thrombolysis for AIS [16].  The large sample of a broad range of AIS 
patients who had systematic outcome assessments are strengths of the ENCHANTED trial.  
However, a clear limitation is the inability to systematically confirm the presence of large vessel 
occlusion angiographically, although there is clear correlation between NIHSS scores and large 
vessel occlusion on arteriogram.  An additional consideration is the generalizability of the 
findings with reference to 90-day outcome, particularly if the hypothesis of BP lowering in the 
presence of impaired autoregulation associated with severe AIS is to be considered [14].  
Concerns over generalizability may also be raised by the majority of the cohort being Asian but 
it could be argued that this ethnic group may be at high risk of risks of hypoperfusion and 
worsening ischemia from their a high prevalence of intracranial atheromatous disease and 
cerebral small vessel disease.  In addition, without data on carotid status, we are unable to infer 
whether this contributed to potential risks of hypoperfusion and subsequent mortality [11].  
Lastly, we did not assess whether recanalization occurred, or the extent to which BP varied, 
within the first 24 hours post-AIS, which is relevant to systolic BP variability and outcomes 
[17].  
In summary, our study has shown that in patients suffering severe AIS, intensive BP lowering 
treatment showed benefits of reduced ICH and increased odds of death, without this translating 
into any over change in functional recovery.  Given the increasing use of endovascular 
thrombectomy in severe AIS, there is urgent need to establish the most appropriate level of BP 
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Table 1. Baseline characteristics in patients with severe acute ischemic stroke 





 P value 
Time from onset to randomization, hr 3.3 (2.6 - 4.0) 3.3 (2.5 - 4.1)  0.961 
Age, yr 67.4 (11.8) 67.1 (12.4)  0.852 
Female 255 (38.1) 225 (35.0)  0.249 
Asian  549 (82.1) 507 (79.0)  0.158 
Systolic BP, mmHg 165 (9) 165 (9)  0.972 
Diastolic BP, mmHg 91 (11) 91 (12)  0.824 
Heart rate, b.p.m. 79 (15) 79 (15)  0.832 
Alteplase dose, mg 0.8 (0.1) 0.8 (0.1)  0.702 
Glasgow coma score 14(13 - 15) 14 (12 - 15)  0.381 
NIHSS 11 (6 - 15) 11 (6 - 15)  0.647 
History of hypertension 478 (71.4) 460 (71.8)  0.900 
Antihypertensive agent(s) use 286 (42.8) 290 (45.2)  0.364 
History of stroke 137 (20.5) 138 (21.5)  0.651 
History of coronary artery disease 105 (15.7) 116 (18.1)  0.246 
History of other heart disease 35 (5.2) 28 (4.4)  0.465 
History of diabetes mellitus 156 (23.3) 139 (21.7)  0.479 
History of hypercholesterolemia 62 (9.3) 63 (9.8)  0.730 
Cigarette smoker 145 (21.7) 128 (20.0)  0.456 
Premorbid function     
  mRS score 0 577 (86.2) 545 (85.0)  0.527 
  mRS score 1 92 (13.8) 96 (15.0)  
 
Antiplatelet use 108 (16.1) 91 (14.2)  0.326 
Anticoagulant use 10 (1.5) 9 (1.4)  0.891 
Glucose lowering therapy 91 (13.6) 77 (12.0)  0.390 
Lipid lowering therapy 81 (12.1) 80 (12.5)  0.837 
Values are n (%), mean (SD) or median (iqr) 
BP denotes blood pressure, mRS modified Rankin scale, NIHSS National Institutes of Health 




Table 2. Efficacy and safety outcomes at 90 days in patients with severe acute ischemic stroke 
 BP lowering group    
Outcome Guideline (n/N, %)  Intensive (n/N, %) Odds ratio (95% CI) P value 
Death or disability at 90 days (mRS scores 2-6) 378/667 (56.7) 368/638 (57.7) 1.04 (0.84-1.3) 0.713 
Death or major disability at 90 days (mRS scores 3-6) 283/667 (42.4) 283/638 (44.4) 1.08 (0.87-1.35) 0.482 
Death within 90 days 67/669 (10.0) 93/642 (14.5) 1.52 (1.09-2.13) 0.014 
Death or neurological deterioration in 24 hours 78/ 669 (11.7) 86/642 (13.4) 1.17 (0.84-1.63) 0.342 
Death or neurological deterioration in 7 days 106/669 (15.8) 124/642 (19.3) 1.27 (0.96-1.69) 0.099 
Symptomatic intracerebral hemorrhage     
  SITS-MOST criteria 16/669 (2.4) 11/642 (1.7) 0.71 (0.33-1.55) 0.390 
  NINDS criteria 67/669 (10.0) 61/642 (9.5) 0.94 (0.65-1.36) 0.754 
  ECASS2 criteria 43/669 (6.4) 41/642 (6.4) 0.99 (0.64-1.55) 0.976 
  ECASS3 criteria 20/669 (3.0) 18/642 (2.8) 0.94 (0.49-1.79) 0.841 
  IST-3 criteria 25/669 (3.7) 21/642 (3.3) 0.87 (0.48-1.57) 0.647 
  Clinician-reported 75/669 (11.2) 47/642 (7.3) 0.63 (0.43-0.92) 0.016 
  Fatal (≤7 days) 10/669 (1.5) 4/642 (0.6) 0.41 (0.13-1.32) 0.137 
Any adjudicated intracerebral hemorrhage 142/669 (21.2) 118/642 (18.4) 0.84 (0.64-1.1) 0.197 
Any intracranial hemorrhage 164/669 (24.5) 130/642 (20.2) 0.78 (0.6-1.01) 0.065 
BP denotes blood pressure, CI confidence interval, ECASS European Co-operative Acute Stroke Study, IST International Stroke Trial, mRS 
modified Rankin Scale, NINDS National Institute of Neurological Disorders and Stroke, SITS-MOST Safe Implementation of Thrombolysis in 






Figure 1. Mean systolic and diastolic blood pressure from randomization to Day 7 in 1,311 patients with severe acute ischemic stroke 
 









Footnote:  BP denotes blood pressure 
